Ryan Kelley

USPTO Granted Patents = 24 (Patent Applications = 9)

CIPO Patents = 3 (Patent Applications = 9)

EPO Patents = 8 (Patent Applications = 18)

Average Co-Inventor Count = 3.5

ph-index = 4

Forward Citations = 48(Granted Patents)

Location History:

Frisco, TX (US) (2015 - 2018)
Pacifica, CA (US) (2015 - 2024)
San Diego, CA (US) (2021 - 2024)

Company Filing History:

13 out of 488

Rigel Pharmaceuticals, Incorporated

Element Biosciences, Inc.

patents

4. 2 out of 832,843

Other

patents

Years Active: 2015-2025

Loading Chart...

24 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12359193 - Single-stranded splint strands and methods of use (2025-07-15),

2. 11993594 - IRAK inhibitors and method for making and using (2024-05-28),

3. 11990208 - Methods for accurate computational decomposition of DNA mixtures from contributors of unknown genotypes (2024-05-21),

4. 11891600 - Nucleic acid indexing techniques (2024-02-06),

5. 11814678 - Universal short adapters for indexing of polynucleotide samples (2023-11-14),

6. 11788139 - Optimal index sequences for multiplex massively parallel sequencing (2023-10-17),

7. 11495325 - Systems and methods for multiplex PCR primer selection (2022-11-08),

8. 11492349 - IRAK inhibitors and method for making and using (2022-11-08),

9. 11456055 - Genotyping polyploid loci (2022-09-27),

10. 11370808 - Pyrazole compounds and methods for making and using the compounds (2022-06-28),

11. 11028436 - Universal short adapters for indexing of polynucleotide samples (2021-06-08),

12. 11028435 - Optimal index sequences for multiplex massively parallel sequencing (2021-06-08),

13. 10941140 - IRAK inhibitors and method for making and using (2021-03-09),

14. 10370367 - IRAK inhibitors and method for making and using (2019-08-06),

15. 10208075 - Pyrazole compounds and method for making and using the compounds (2019-02-19),

Title: The Innovations of Ryan Kelley: A Pioneer in IRAK Inhibitors

Introduction: Ryan Kelley, an esteemed inventor based in Pacifica, CA, has made significant contributions to the field of biopharmaceuticals. With a remarkable portfolio of 13 patents to his name, Kelley focuses on the development of innovative compounds and methods that address critical health issues related to interleukin receptor-associated kinases (IRAK).

Latest Patents: Kelley's most recent patents include groundbreaking technologies involving IRAK inhibitors, particularly oxazole compounds. These patents detail methods for creating and utilizing these compounds and compositions. With potential applications in treating or preventing IRAK-associated diseases or conditions, his work reflects a commitment to advancing healthcare through innovation.

Career Highlights: Ryan Kelley has established himself as a formidable force in the biopharmaceutical industry. He is currently associated with Rigel Pharmaceuticals, Incorporated, where he continues to explore new frontiers in therapeutic development. His expertise and innovative mindset have positioned him as a key contributor to the company's research initiatives.

Collaborations: Throughout his career, Kelley has collaborated with prominent professionals in the field, including Kin Tso and Thilo J Heckrodt. These partnerships have enhanced the scope of his research and facilitated the successful translation of innovative ideas into viable therapeutic solutions.

Conclusion: Ryan Kelley's dedication to innovation in the realm of IRAK inhibitors exemplifies the impact that inventors can have on society. With his extensive experience and a robust portfolio of patents, Kelley continues to pave the way for future advancements in healthcare, demonstrating the vital role that inventors play in improving human health and well-being.

This text is generated by artificial intelligence and may not be accurate.